Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Sep 10;15:7930. doi: 10.1038/s41467-024-52170-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — A The effect of STING-KD on the tumor growth of PRMT3-KO Hepa1-6 cells as shown by measurement of tumor volumes (n = 6). B The effect of STING-KD on the tumor growth of PRMT3-KO Hepa1-6 cells as shown by tumor weights at the endpoint of the experiment on day 14 (n = 6). C CD4⁺ and CD8⁺ T cells from the treated tumors were analyzed by flow cytometry for the indicated groups (sgNC, sgPRMT3, sgNC + shSTING, and sgPRMT3 + shSTING) (n = 5). Data were analyzed by FlowJo. D Flow cytometry analysis assessing the percentage of T cell functional markers IFNγ and GZMB from tumors in indicated groups. (sgNC, sgPRMT3, sgNC + shSTING and sgPRMT3 + shSTING) (n = 5). Data were analyzed by FlowJo. E The effects of STING-KD on the expression of ISGs in tumors from PRMT3-KO Hepa1-6 cells (n = 3 biologically independent samples). F The effects of STING-KD on the IFNβ production in tumors from PRMT3-KO Hepa1-6 cells as detected by ELISA assay (n = 3 biologically independent samples). G, H The effects of SGC707/RU.521 treatment on tumor volumes of Myc/Trp53^−/− spontaneous model (n = 6). CD4⁺ (I) and CD8⁺ (J) T cells from tumors were analyzed by flow cytometry in indicated groups (DMSO, SGC707, RU.521, and Combo) (n = 5). Data were analyzed by FlowJo. Flow cytometry analysis assessing the percentage of T cell functional markers IFNγ (K) and GZMB (L) from tumors in indicated groups (DMSO, SGC707, RU.521, and Combo) (n = 5). Data were analyzed by FlowJo. M The effects of SGC707/RU.521 treatment on the expression of ISGs in Myc/Trp53^−/− spontaneous model as shown by qRT-PCR (n = 3 biologically independent samples). N The effects of SGC707/RU.521 treatment on IFNβ production in Myc/Trp53^−/− spontaneous model as detected by ELISA assay (n = 3 biologically independent samples). O The effect of cGAS-KD on the tumor growth of PRMT3-KO Hepa1-6 cells as shown by measurement of tumor volumes (n = 6). P The effect of cGAS-KD on the tumor growth of PRMT3-KO Hepa1-6 cells as shown by tumor weights at the endpoint of the experiment on day 14 (n = 6). Q CD4⁺ and CD8⁺ T cells from the treated tumors were analyzed by flow cytometry for the indicated groups (sgNC, sgPRMT3, sgNC + shcGAS and sgPRMT3 + shcGAS) (n = 5). Data were analyzed by FlowJo. R Flow cytometry analysis assessing the percentage of T cell functional markers IFNγ and GZMB from tumors in indicated groups (sgNC, sgPRMT3, sgNC + shcGAS and sgPRMT3 + shcGAS) (n = 5). Data were analyzed by FlowJo. S The effects of cGAS-KD on the expression of ISGs in tumors from PRMT3-KO Hepa1-6 cells (n = 3 biologically independent samples). T The effects of cGAS-KD on the IFNβ production in tumors from PRMT3-KO Hepa1-6 cells as detected by ELISA assay (n = 3 biologically independent samples). Data in (A–E, H–T) are presented as mean ± SD. Data were analyzed by one-way ANOVA in (A–E, H–T). Source data are provided as a Source Data file.